Metabolic Effects of Known and Novel HDAC and SIRT Inhibitors in Glioblastomas Independently or Combined with Temozolomide

Inhibition of protein deacetylation enzymes, alone or in combination with standard chemotherapies, is an exciting addition to cancer therapy. We have investigated the effect of deacetylase inhibition on the metabolism of glioblastoma cells. 1H NMR metabolomics analysis was used to determine the majo...

Full description

Bibliographic Details
Published in:	Metabolites
Main Authors:	Miroslava Cuperlovic-Culf, Mohamed Touaibia, Patrick-Denis St-Coeur, Julie Poitras, Pier Morin, Adrian S. Culf
Format:	Article
Language:	English
Published:	MDPI AG 2014-09-01
Subjects:	metaboloepigenomics NMR metabolomics glioblastoma enzyme inhibitors combined treatment
Online Access:	http://www.mdpi.com/2218-1989/4/3/807

Similar Items

Analysis and Simulation of Glioblastoma Cell Lines-Derived Extracellular Vesicles Metabolome
by: Miroslava Čuperlović-Culf, et al.
Published: (2020-03-01)

Automatic 1D <sup>1</sup>H NMR Metabolite Quantification for Bioreactor Monitoring
by: Roy Chih Chung Wang, et al.
Published: (2021-03-01)

Substituted Caffeic and Ferulic Acid Phenethyl Esters: Synthesis, Leukotrienes Biosynthesis Inhibition, and Cytotoxic Activity
by: Pier Morin, et al.
Published: (2017-07-01)

Quinacrine enhances temozolomide cytotoxicity in temozolomide-sensitive and -resistant glioblastoma cells
by: Pingde Zhang, et al.
Published: (2018-01-01)

Importance of Autophagy Regulation in Glioblastoma with Temozolomide Resistance
by: Young Keun Hwang, et al.
Published: (2024-08-01)

Temozolomide Resistance in Glioblastoma by NRF2: Protecting the Evil
by: Karoline Almeida Lima, et al.
Published: (2023-04-01)

Integrins and p53 pathways in glioblastoma resistance to temozolomide
by: Monique eDontenwill, et al.
Published: (2012-10-01)

Molecular Mechanisms of KDELC2 on Glioblastoma Tumorigenesis and Temozolomide Resistance
by: Yu-Ling Tsai, et al.
Published: (2020-09-01)

Considering the Experimental Use of Temozolomide in Glioblastoma Research
by: Verena J. Herbener, et al.
Published: (2020-06-01)

Synergistic effect of perampanel with temozolomide on glioblastoma cells in vivo
by: Takuma Nishide, et al.
Published: (2025-03-01)

MicroRNAs as the pivotal regulators of Temozolomide resistance in glioblastoma
by: Mahsa Palizkaran Yazdi, et al.
Published: (2024-07-01)

Meningeal seeding from glioblastoma multiforme treated with radiotherapy and temozolomide
by: Lu-Ting Kuo, et al.
Published: (2017-01-01)

Outcomes of pediatric glioblastoma treated with adjuvant chemoradiation with temozolomide and correlation with prognostic factors
by: Supriya Mallick, et al.
Published: (2015-01-01)

Patterns of recurrence and outcomes of glioblastoma multiforme treated with chemoradiation and adjuvant temozolomide
by: Alexandre Ciuffi Faustino, et al.
Published: (2020-09-01)

The Role of HDAC6 in Glioblastoma Multiforme: A New Avenue to Therapeutic Interventions?
by: Francesco Spallotta, et al.
Published: (2024-11-01)

Kalata B1 Enhances Temozolomide Toxicity to Glioblastoma Cells
by: Samantha L. Gerlach, et al.
Published: (2024-09-01)

Nanomedicine-based combination therapies for overcoming temozolomide resistance in glioblastomas
by: Chun Wang, et al.
Published: (2023-05-01)

Gossypol Suppresses Growth of Temozolomide-Resistant Glioblastoma Tumor Spheres
by: Hee Yeon Kim, et al.
Published: (2019-10-01)

Combining HDAC and MEK Inhibitors with Radiation against Glioblastoma-Derived Spheres
by: Eno I. Essien, et al.
Published: (2022-02-01)

Radiotherapy with or without temozolomide in elderly patients aged ≥ 70 years with glioblastoma
by: Evrim Metcalfe, et al.
Published: (2016-08-01)

Toxicity after radiochemotherapy for glioblastoma using temozolomide - a retrospective evaluation
by: Niewald Marcus, et al.
Published: (2011-10-01)

Introducing HDAC-Targeting Radiopharmaceuticals for Glioblastoma Imaging and Therapy
by: Liesbeth Everix, et al.
Published: (2023-02-01)

TTK Protein Kinase promotes temozolomide resistance through inducing autophagy in glioblastoma
by: Jian Yu, et al.
Published: (2022-07-01)

Survival benefits of hypofractionated radiotherapy combined with temozolomide or temozolomide plus bevacizumab in elderly patients with glioblastoma aged ≥ 75 years
by: Makoto Ohno, et al.
Published: (2019-11-01)

Temozolomide resistance in glioblastoma: a non-coding RNA viewpoint
by: Maryam Motallebinezhad, et al.
Published: (2025-12-01)

Siderol Inhibits Proliferation of Glioblastoma Cells and Acts Synergistically with Temozolomide
by: Maria Giannakopoulou, et al.
Published: (2022-12-01)

Apatinib Plus Temozolomide: An Effective Salvage Treatment for Recurrent Glioblastoma
by: Jingjing Ge, et al.
Published: (2021-02-01)

Phase II trial of upfront bevacizumab and temozolomide for unresectable or multifocal glioblastoma
by: Emil Lou, et al.
Published: (2013-04-01)

Stanniocalcin-1 promotes temozolomide resistance of glioblastoma through regulation of MGMT
by: Chao Duan, et al.
Published: (2024-08-01)

Gene signatures associated with prognosis and chemotherapy resistance in glioblastoma treated with temozolomide
by: Tonia Carter, et al.
Published: (2023-12-01)

Identifying Predictive Gene Expression and Signature Related to Temozolomide Sensitivity of Glioblastomas
by: Hong-Qing Cai, et al.
Published: (2020-05-01)

Efficacy of systemic temozolomide‐activated phage‐targeted gene therapy in human glioblastoma
by: Justyna Magdalena Przystal, et al.
Published: (2019-02-01)

Iloperidone and Temozolomide Synergistically Inhibit Growth, Migration and Enhance Apoptosis in Glioblastoma Cells
by: Sahar Mubeen, et al.
Published: (2024-05-01)

Panobinostat Potentiates Temozolomide Effects and Reverses Epithelial–Mesenchymal Transition in Glioblastoma Cells
by: Alejandro Urdiciain, et al.
Published: (2018-02-01)

Comparison of multi-cycle and standard-cycle temozolomide chemotherapies in patients with glioblastoma undergoing surgery and successive radiotherapy
by: Yuan Fu, et al.
Published: (2023-06-01)

Molecular Evolution of a Glioblastoma Controlled With Tumor Treating Fields and Concomitant Temozolomide
by: H. Ian Robins, et al.
Published: (2018-10-01)

Synergistic Effects of Temozolomide and Doxorubicin in the Treatment of Glioblastoma Multiforme: Enhancing Efficacy through Combination Therapy
by: Laxmi Dhungel, et al.
Published: (2024-02-01)

Targeted c-Myc Inhibition and Systemic Temozolomide Therapy Extend Survival in Glioblastoma Xenografts
by: Laxmi Dhungel, et al.
Published: (2023-06-01)

rAAV Manufacturing: The Challenges of Soft Sensing during Upstream Processing
by: Cristovão Freitas Iglesias, et al.
Published: (2023-02-01)

LAPTM5–CD40 Crosstalk in Glioblastoma Invasion and Temozolomide Resistance
by: Anne Berberich, et al.
Published: (2020-06-01)